In vitro, the treatment of AML-12 cells with Nrf2 inhibitor ML385 resulted in an increase in mtROS, a reduction in PPARγ and SOD2 expression, and a reversal of the DDB-induced down-regulation of p-MLKL. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.